Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib as neoadjuvant treatment for HER2-positive breast cancer
ChiCTR2200062936Phase 4Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Sep 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pyrotinib in breast cancer, sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Pathologic Complete Response. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2200062936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062936.